mp.weixin.qq.com·· 7 hours agoPickScore64
Generate Biomedicines and Zealand Pharma Strike $1.2 Billion Metabolic Protein Therapy Deal
In brief
Generate Biomedicines and Zealand Pharma entered a multi-target strategic collaboration and licensing agreement worth up to $1.2 billion on October 13, 2026. Using The Generate platform, the companies will jointly design multi-specific protein therapies for obesity and other metabolic diseases, with experimental data used to continually optimize molecular design.
Why it matters
The deal combines Zealand Pharma's metabolic disease expertise with Generate's generative AI and experimental validation to co-develop multi-specific protein therapies for obesity.
Source: mp.weixin.qq.com · mp.weixin.qq.com